Literature DB >> 26936940

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Adam J Schwarz1, Peng Yu2, Bradley B Miller2, Sergey Shcherbinin2, James Dickson3, Michael Navitsky3, Abhinay D Joshi3, Michael D Devous3, Mark S Mintun3.   

Abstract

SEE THAL AND VANDENBERGHE DOI101093/BRAIN/AWW057 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Post-mortem Braak staging of neurofibrillary tau tangle topographical distribution is one of the core neuropathological criteria for the diagnosis of Alzheimer's disease. The recent development of positron emission tomography tracers targeting neurofibrillary tangles has enabled the distribution of tau pathology to be imaged in living subjects. Methods for extraction of classic Braak staging from in vivo imaging of neurofibrillary tau tangles have not yet been explored. Standardized uptake value ratio images were calculated from 80-100 minute (18)F-AV-1451 (also known as T807) positron emission tomography scans obtained from n = 14 young reference subjects (age 21-39 years, Mini-Mental State Examination 29-30) and n = 173 older test subjects (age 50-95 years) comprising amyloid negative cognitively normal (n = 42), clinically-diagnosed mild cognitive impairment (amyloid positive, n = 47, and amyloid negative, n = 40) and Alzheimer's disease (amyloid positive, n = 28, and amyloid negative, n = 16). We defined seven regions of interest in anterior temporal lobe and occipital lobe sections corresponding closely to those used as decision points in Braak staging. An algorithm based on the Braak histological staging procedure was applied to estimate Braak stages directly from the region of interest profiles in each subject. Quantitative region-based analysis of (18)F-AV-1451 images yielded region of interest and voxel level profiles that mirrored key features of neuropathological tau progression including profiles consistent with Braak stages 0 through VI. A simple set of decision rules enabled plausible Braak stages corresponding to stereotypical progression patterns to be objectively estimated in 149 (86%) of test subjects. An additional 12 (7%) subjects presented with predefined variant profiles (relative sparing of the hippocampus and/or occipital lobe). The estimated Braak stage was significantly associated with amyloid status, diagnostic category and measures of global cognition. In vivo (18)F-AV-1451 positron emission tomography images across the Alzheimer's disease spectrum could be classified into patterns similar to those prescribed by Braak neuropathological staging of tau pathology.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  18F-AV-1451; Braak staging; imaging; positron emission tomography (PET); tau

Mesh:

Substances:

Year:  2016        PMID: 26936940     DOI: 10.1093/brain/aww023

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  180 in total

1.  Structure-based inhibitors of amyloid beta core suggest a common interface with tau.

Authors:  Sarah L Griner; Paul Seidler; Jeannette Bowler; Kevin A Murray; Tianxiao Peter Yang; Shruti Sahay; Michael R Sawaya; Duilio Cascio; Jose A Rodriguez; Stephan Philipp; Justyna Sosna; Charles G Glabe; Tamir Gonen; David S Eisenberg
Journal:  Elife       Date:  2019-10-15       Impact factor: 8.140

2.  [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.

Authors:  Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla
Journal:  Acta Neuropathol       Date:  2017-06-13       Impact factor: 17.088

3.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography.

Authors:  Michelle M Mielke; Clinton E Hagen; Jing Xu; Xiyun Chai; Prashanthi Vemuri; Val J Lowe; David C Airey; David S Knopman; Rosebud O Roberts; Mary M Machulda; Clifford R Jack; Ronald C Petersen; Jeffrey L Dage
Journal:  Alzheimers Dement       Date:  2018-04-05       Impact factor: 21.566

4.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

Review 5.  The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.

Authors:  David S Knopman; Samantha Budd Haeberlein; Maria C Carrillo; James A Hendrix; Geoff Kerchner; Richard Margolin; Paul Maruff; David S Miller; Gary Tong; Maria B Tome; Melissa E Murray; Peter T Nelson; Mary Sano; Niklas Mattsson; David L Sultzer; Thomas J Montine; Clifford R Jack; Hartmuth Kolb; Ronald C Petersen; Prashanthi Vemuri; Megan Zoschg Canniere; Julie A Schneider; Susan M Resnick; Gary Romano; Argonde Corien van Harten; David A Wolk; Lisa J Bain; Eric Siemers
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

6.  Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease.

Authors:  Nicolai Franzmeier; Anna Rubinski; Julia Neitzel; Yeshin Kim; Alexander Damm; Duk L Na; Hee Jin Kim; Chul Hyoung Lyoo; Hana Cho; Sofia Finsterwalder; Marco Duering; Sang Won Seo; Michael Ewers
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

7.  Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Authors:  Kerstin Heurling; Ruben Smith; Olof T Strandberg; Martin Schain; Tomas Ohlsson; Oskar Hansson; Michael Schöll
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-03       Impact factor: 6.200

8.  Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau.

Authors:  Jennifer S Rabin; Hyun-Sik Yang; Aaron P Schultz; Bernard J Hanseeuw; Trey Hedden; Anand Viswanathan; Jennifer R Gatchel; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Vaishnavi Rao; Rachel F Buckley; Wai-Ying Wendy Yau; Dylan R Kirn; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  Ann Neurol       Date:  2019-01-07       Impact factor: 10.422

9.  Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Authors:  Dean F Wong; Robert A Comley; Hiroto Kuwabara; Paul B Rosenberg; Susan M Resnick; Susanne Ostrowitzki; Cristina Vozzi; Frank Boess; Esther Oh; Constantine G Lyketsos; Michael Honer; Luca Gobbi; Gregory Klein; Noble George; Lorena Gapasin; Kelly Kitzmiller; Josh Roberts; Jeff Sevigny; Ayon Nandi; James Brasic; Chakradhar Mishra; Madhav Thambisetty; Abhay Mogekar; Anil Mathur; Marilyn Albert; Robert F Dannals; Edilio Borroni
Journal:  J Nucl Med       Date:  2018-05-04       Impact factor: 10.057

10.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.